These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 18455581)

  • 1. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
    Kandioler D; Stamatis G; Eberhardt W; Kappel S; Zöchbauer-Müller S; Kührer I; Mittlböck M; Zwrtek R; Aigner C; Bichler C; Tichy V; Hudec M; Bachleitner T; End A; Müller MR; Roth E; Klepetko W
    J Thorac Cardiovasc Surg; 2008 May; 135(5):1036-41. PubMed ID: 18455581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients.
    Boulay JL; Perruchoud AP; Reuter J; Bolliger C; Herrmann R; Rochlitz C
    Cancer Gene Ther; 2000 Sep; 7(9):1215-9. PubMed ID: 11023193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of p53 gene in stage IIIA non-small cell lung cancer in patients after neoadjuvant chemotherapy with Vepesid and Cisplatin.
    Mańdziuk S; Dudzisz-Sledź M; Korszeń-Pilecka I; Milanowski J; Wojcierowski J; Korobowicz E
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):154-7. PubMed ID: 15314976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
    Swisher SG; Roth JA; Komaki R; Gu J; Lee JJ; Hicks M; Ro JY; Hong WK; Merritt JA; Ahrar K; Atkinson NE; Correa AM; Dolormente M; Dreiling L; El-Naggar AK; Fossella F; Francisco R; Glisson B; Grammer S; Herbst R; Huaringa A; Kemp B; Khuri FR; Kurie JM; Liao Z; McDonnell TJ; Morice R; Morello F; Munden R; Papadimitrakopoulou V; Pisters KM; Putnam JB; Sarabia AJ; Shelton T; Stevens C; Shin DM; Smythe WR; Vaporciyan AA; Walsh GL; Yin M
    Clin Cancer Res; 2003 Jan; 9(1):93-101. PubMed ID: 12538456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of p21 and bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage IIIA after Etoposide and Cisplatin induced chemotherapy.
    Mańdziuk S; Dudzisz-Sledź M; Korszeń-Pilecka I; Milanowski J; Wojcierowski J; Korobowicz E
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):149-53. PubMed ID: 15314975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer.
    Vogt U; Zaczek A; Klinke F; Granetzny A; Bielawski K; Falkiewicz B
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):141-7. PubMed ID: 11935300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.
    Kandioler-Eckersberger D; Kappel S; Mittlböck M; Dekan G; Ludwig C; Janschek E; Pirker R; Wolner E; Eckersberger F
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):744-50. PubMed ID: 10096970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus.
    Heeren PA; Kloppenberg FW; Hollema H; Mulder NH; Nap RE; Plukker JT
    Anticancer Res; 2004; 24(4):2579-83. PubMed ID: 15330218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
    Milman S; Kim AW; Warren WH; Liptay MJ; Miller C; Basu S; Faber LP
    Ann Thorac Surg; 2009 Sep; 88(3):945-50; discussion 950-1. PubMed ID: 19699925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer.
    Sohn JW; Lee SY; Lee SJ; Kim EJ; Cha SI; Kim CH; Lee JT; Jung TH; Park JY
    Jpn J Clin Oncol; 2006 Mar; 36(3):137-41. PubMed ID: 16478794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assessment of induction therapy and resection in stage IIIb non-small cell lung cancer].
    Togashi K; Sugawara M; Miyamura H; Sato Y; Kourakata H; Nishibori T; Saito H; Sato K
    Kyobu Geka; 1999 Nov; 52(12):1016-9. PubMed ID: 10554488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical strategies and outcomes after induction therapy for non-small cell lung cancer.
    Burfeind WR; Harpole DH
    Semin Thorac Cardiovasc Surg; 2005; 17(3):186-90. PubMed ID: 16253820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
    Filipits M; Pirker R; Dunant A; Lantuejoul S; Schmid K; Huynh A; Haddad V; André F; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Brambilla E
    J Clin Oncol; 2007 Jul; 25(19):2735-40. PubMed ID: 17602078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.
    Rusch V; Klimstra D; Venkatraman E; Oliver J; Martini N; Gralla R; Kris M; Dmitrovsky E
    Cancer Res; 1995 Nov; 55(21):5038-42. PubMed ID: 7585548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
    Jhawer M; Coit D; Brennan M; Qin LX; Gonen M; Klimstra D; Tang L; Kelsen DP; Shah MA
    Am J Clin Oncol; 2009 Aug; 32(4):356-62. PubMed ID: 19381079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.
    Roth JA; Swisher SG; Merritt JA; Lawrence DD; Kemp BL; Carrasco CH; El-Naggar AK; Fossella FV; Glisson BS; Hong WK; Khurl FR; Kurie JM; Nesbitt JC; Pisters K; Putnam JB; Schrump DS; Shin DM; Walsh GL
    Semin Oncol; 1998 Jun; 25(3 Suppl 8):33-7. PubMed ID: 9704675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer.
    d'Amato TA; Ashrafi AS; Schuchert MJ; Alshehab DS; Seely AJ; Shamji FM; Maziak DE; Sundaresan SR; Ferson PF; Luketich JD; Landreneau RJ
    Ann Thorac Surg; 2009 Oct; 88(4):1079-85. PubMed ID: 19766784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic strategies in superior sulcus tumors: a model for combined modality therapy in non-small cell lung cancer].
    Girard N; Mornex F
    Cancer Radiother; 2007; 11(1-2):59-66. PubMed ID: 17197220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.